Some have argued that the approval of Veklury is justified even if it is only mildly effective because there are no other proven therapies for Covid-19.
This fails to acknowledge, however, the proven effectiveness of drugs like dexamethasone, a cheap and widely used steroid.
Weaker standards are a boon to pharmaceutical companies, but they can also depress the development of truly innovative and effective treatments.
granted an authorization to an antibody treatment called bamlanivimab, for use in non-hospitalized patients with Covid-19 who are at the highest risk of developing severe disease.
This may have been possible only because Veklury was approved specifically for hospitalized patients.